Valuation: AC Immune SA

Market Cap 202M 250M 219M 187M 355M 23.94B 362M 2.43B 946M 11.71B 939M 918M 40.66B P/E 2026 *
-6.98x
P/E 2027 * 371x
Enterprise Value 158M 195M 171M 146M 276M 18.64B 282M 1.89B 736M 9.12B 731M 715M 31.66B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 3.12x
Free-Float
56.09%
Yield 2026 *
-
Yield 2027 * -
1 day+1.59%
1 week+2.79%
Current month+8.40%
1 month+14.16%
3 months-24.12%
6 months-24.34%
Current year-17.83%
1 week 2.47
Extreme 2.47
2.63
1 month 2.1
Extreme 2.095
2.66
Current year 2.1
Extreme 2.095
3.9
1 year 2
Extreme 2
4
3 years 1.43
Extreme 1.4299
5.14
5 years 1.43
Extreme 1.4299
12.61
10 years 1.43
Extreme 1.4299
19.97
Manager TitleAgeSince
Chief Executive Officer 64 2026-06-10
Director of Finance/CFO 37 2021-12-31
Chief Tech/Sci/R&D Officer 45 2012-12-31
Director TitleAgeSince
Director/Board Member 70 2018-12-31
Director/Board Member 72 2020-11-19
Director/Board Member 65 2021-10-28
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Director

55,457 0.0545%
06-10Free

Chief Executive Officer

110,914 0.1090%
06-10Free

Director

55,457 0.0545%
Change 5-day change 1-year change 3-year change Capi.($)
+1.59%+2.79%+24.04%-16.50% 250M
+0.24%+1.37%+20.03%-5.70% 67.44B
+2.21%-3.89%+49.32%+224.20% 53.98B
-4.15%+36.30%+36.30%+36.30% 41.77B
+0.99%+6.61%-48.49%-52.47% 41.15B
-1.01%-8.44%+48.75%-29.73% 29.58B
+3.21%-5.57%+129.70%-38.81% 29.28B
+0.84%+1.01%+71.76%+90.72% 23.43B
+0.17%+1.17%+4.98%+190.25% 19.11B
+0.84%-0.54%+68.19%+133.59% 16.82B
Average +0.47%+2.12%+40.46%+53.18% 32.28B
Weighted average by Cap. +0.31%+1.53%+36.26%+52.86%

Financials

2026 *2027 *
Net sales 36.27M 44.79M 39.28M 33.52M 63.52M 4.29B 64.8M 436M 169M 2.1B 168M 165M 7.29B 70.26M 86.76M 76.1M 64.92M 123M 8.31B 126M 845M 328M 4.07B 326M 319M 14.11B
Net income -30.38M -37.52M -32.91M -28.07M -53.21M -3.59B -54.28M -365M -142M -1.76B -141M -138M -6.1B -336K -415K -364K -310K -588K -39.7M -600K -4.04M -1.57M -19.43M -1.56M -1.52M -67.45M
Net Debt -44.8M -55.33M -48.53M -41.4M -78.47M -5.3B -80.04M -539M -209M -2.59B -208M -203M -9B 17.1M 21.12M 18.52M 15.8M 29.95M 2.02B 30.55M 206M 79.87M 990M 79.3M 77.56M 3.43B
Logo AC Immune SA
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Employees
106
Date Price Change Volume
26-07-09 US$2.580 +2.38% 19,621
26-07-08 US$2.520 -0.79% 164,076
26-07-07 US$2.540 +1.20% 141,480
26-07-06 US$2.510 0.00% 269,247
26-07-02 US$2.510 +5.46% 364,873
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.041CHF
Average target price
6.885CHF
Spread / Average Target
+237.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACIU Stock